BIOGEN INC. - COMMON STOCK

Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors

08 3 2023 07:30:00 提供 Nasdaq GlobeNewswire

FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

05 3 2023 18:30:00 提供 Nasdaq GlobeNewswire

Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration

27 2 2023 18:30:00 提供 Nasdaq GlobeNewswire

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

06 2 2023 06:30:00 提供 Nasdaq GlobeNewswire

Lecanemab Receives Priority Review Status in Japan

29 1 2023 18:30:00 提供 Nasdaq GlobeNewswire

Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

26 1 2023 18:30:00 提供 Nasdaq GlobeNewswire

Biogen Names Priya Singhal as Executive Vice President, Head of Development

05 1 2023 07:30:00 提供 Nasdaq GlobeNewswire

Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies

04 1 2023 07:30:00 提供 Nasdaq GlobeNewswire

Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration

19 12 2022 07:30:00 提供 Nasdaq GlobeNewswire

FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)

09 12 2022 07:30:00 提供 Nasdaq GlobeNewswire

European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS

05 12 2022 07:30:00 提供 Nasdaq GlobeNewswire

Biogen Names Christopher Viehbacher President and Chief Executive Officer

10 11 2022 07:30:01 提供 Nasdaq GlobeNewswire

Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS

26 10 2022 06:05:00 提供 Nasdaq GlobeNewswire

New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS

26 10 2022 06:02:00 提供 Nasdaq GlobeNewswire

Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen

17 10 2022 07:30:10 提供 Nasdaq GlobeNewswire

Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)

30 9 2022 07:00:00 提供 Nasdaq GlobeNewswire

The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS

21 9 2022 17:15:12 提供 Nasdaq GlobeNewswire

The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus

07 9 2022 17:45:26 提供 Nasdaq GlobeNewswire

The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus

28 7 2022 07:30:00 提供 Nasdaq GlobeNewswire

FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS

26 7 2022 07:30:02 提供 Nasdaq GlobeNewswire